Drug intelligence / Profile preview

RG014

Development stage: Preclinical
Lead developer: Rigerna Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RG014 is a kidney-targeted small interfering RNA (siRNA) therapeutic being developed by Rigerna Bio. It is designed to treat metabolic and renal diseases by silencing an undisclosed gene target. The drug utilizes Rigerna's proprietary delivery technology to achieve specific targeting of renal tissues, aiming to modulate disease pathways while minimizing systemic exposure. As of early 2026, RG014 is in the Preclinical Candidate (PCC) stage of development.

Beyond the preview

Go deeper on RG014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG014.

Explore the full profile